Patenting Germs? USPTO Updates Forms for Storing Tiny Life Forms
Published Date: 3/9/2026
Notice
Summary
The USPTO is asking for your thoughts on renewing a form that helps patent applicants deposit biological materials, like tiny living things, when applying for patents. This update won’t cost you money but aims to keep paperwork easy and clear. If you want to share your ideas, make sure to comment by April 8, 2026!
Analyzed Economic Effects
4 provisions identified: 0 benefits, 4 costs, 0 mixed.
Estimated Paperwork Burden and Costs
The USPTO estimates 1,501 annual respondents and 1,501 annual responses for this information collection, with each response taking about 1 to 5 hours. The total estimated annual respondent burden is 1,505 hours and the total estimated annual non-hourly cost burden is $4,306,511. Comments on the collection are due by April 8, 2026.
Information You Must Give When Depositing Biologicals
If you submit a patent application that includes a biological material capable of self-replication, you must provide documentation to the USPTO showing compliance with 37 CFR 1.801–1.809. When a deposit is not made under the Budapest Treaty, you must submit a viability statement that includes the depository name and address, depositor name/address, deposit date, deposit identity and accession number, viability test date, sampling procedure (if not done by the depository), and a statement the deposit can reproduce.
What to Report if a Deposit Fails or Changes
If a deposited biological sample is lost, contaminated, or cannot self-replicate, you must notify the USPTO in writing with particulars and, if the patent has already issued, request a certificate of correction. You may also be required to submit verification statements or written notifications that an acceptable deposit will be made after the effective filing date.
Rules to Become a USPTO-Recognized Depository
Institutions that want USPTO recognition as a suitable depository under 37 CFR 1.803(a)(2) must submit detailed information about their name/address, legal status, scientific standing, staff, facilities, the types of biological material they will accept, availability conditions, and any fees they will charge for storage, viability statements, and supplying samples.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16744, Request for Comments on Community Outreach Office Locations in the Southwest States
The USPTO wants your ideas on where to open new community outreach offices in the Southwest states like Arizona and Texas. These offices will help inventors, small businesses, and students get better support with patents. Share your thoughts by September 16, 2026, so the USPTO can pick the best spots and keep innovation booming without extra costs to you!
2026-16315, Administrative Updates to the General Requirements Bulletin for Admission to the Examination for Registration To Practice in Patent Cases Before the United States Patent and Trademark Office
Starting August 11, 2026, the USPTO is upgrading Biomedical Science degrees from Category B to Category A for patent bar eligibility. This means more people with this degree can now take the patent exam and become patent practitioners. No extra fees or delays—just a smoother path for those with the right science background to join the patent world!
2026-14941, Grant of Interim Extension of the Term of U.S. Patent No. 8,461,196; Centanafadine Hydrochloride
Otsuka America Pharmaceutical got a one-year extra patent life for their drug centanafadine hydrochloride because the FDA review is still going on. This means they keep exclusive rights to the drug until July 25, 2027, giving them more time to sell it without competition. This extension helps the company protect their investment while the drug gets final approval.
2026-14939, Grant of Interim Extension of the Term of U.S. Patent No. 8,877,798; Centanafadine Hydrochloride
Otsuka America Pharmaceutical got a one-year extra patent life for their drug centanafadine hydrochloride because the FDA review is still going on. This means their patent, which was set to expire on July 25, 2026, now lasts until July 25, 2027. This extension helps Otsuka keep exclusive rights to their drug a bit longer while waiting for final FDA approval.
2026-14793, Requirement To Identify All Real Parties in Interest to a Third Party Request for an Ex Parte Reexamination
The USPTO wants anyone asking for a third-party ex parte reexamination to clearly say who’s really behind the request. This helps stop sneaky tricks and keeps the process honest. If you’re involved, get ready to share this info confidentially by August 21, 2026, or risk delays or issues.
2026-14388, Agency Information Collection Activities; Submission to the Office of Management and Budget for Review and Approval; Comment Request; Admission to Practice and Roster of Registered Patent Attorneys and Agents Admitted to Practice Before the United States Patent and Trademark Office
The USPTO is asking for public feedback on its paperwork rules for patent attorneys and agents who want to practice before the office. This helps keep the process smooth and fair without making people fill out too many forms. If you have thoughts, send them in by August 17, 2026—no fees or big changes are happening right now, just a review.
Previous / Next Documents
Previous: 2026-04518, Agency Information Collection Activities: Submission for OMB Review; Comment Request
The Centers for Medicare & Medicaid Services (CMS) wants your feedback on their plan to collect some information from the public. This is a routine step to make sure the questions they ask are useful and not too much work. If you have thoughts, you’ve got until April 8, 2026, to share them—no cost, just your voice!
Next: 2026-04521, Certain Off-Road Vehicles and Components Thereof; Notice of Institution of Investigation
Polaris Inc. has asked the U.S. International Trade Commission to investigate certain off-road vehicles and parts that might be breaking their patents. If the investigation finds problems, it could lead to bans on importing and selling these products in the U.S., affecting companies and customers soon. This could shake up the off-road vehicle market and impact sales and availability.